mRNA Platform

mRNA Platform

Global mRNA Platform Market to Reach US$120.2 Billion by 2030

The global market for mRNA Platform estimated at US$149.9 Billion in the year 2023, is expected to reach US$120.2 Billion by 2030, growing at a CAGR of -3.1% over the analysis period 2023-2030. Covid-19 Vaccine, one of the segments analyzed in the report, is expected to record a -6.1% CAGR and reach US$96.5 Billion by the end of the analysis period. Growth in the Cancer Vaccine segment is estimated at 104.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$67.5 Billion While China is Forecast to Grow at -0.8% CAGR

The mRNA Platform market in the U.S. is estimated at US$67.5 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$13.8 Billion by the year 2030 trailing a CAGR of -0.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of -4.2% and -5.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately -3.8% CAGR.

Global mRNA Platform Market - Key Trends & Drivers Summarized

The mRNA platform has emerged as a groundbreaking innovation in the field of biotechnology and pharmaceuticals, revolutionizing the way vaccines and therapeutics are developed and deployed. mRNA, or messenger RNA, acts as a blueprint for protein synthesis within cells, and this technology harnesses that mechanism to instruct cells to produce specific proteins that can trigger an immune response or treat diseases. The success of mRNA-based COVID-19 vaccines, developed by companies like Moderna and Pfizer-BioNTech, has showcased the platform`s potential for rapid and scalable vaccine production. Unlike traditional vaccines, which often require months or years to develop, mRNA vaccines can be designed and manufactured much more quickly, providing a crucial tool in responding to emerging infectious diseases.

Technological advancements have significantly enhanced the capabilities and applications of the mRNA platform. Innovations in lipid nanoparticle (LNP) delivery systems have improved the stability and efficiency of mRNA molecules, allowing for effective delivery into cells. This has broadened the potential applications of mRNA technology beyond vaccines to include treatments for cancer, genetic disorders, and other diseases. The flexibility of the mRNA platform allows for the rapid redesign of vaccines and therapeutics to address new virus variants or different diseases, making it a versatile tool in precision medicine. Additionally, advancements in synthetic biology and bioinformatics have enabled more precise and efficient mRNA sequence design, optimizing the expression and effectiveness of the encoded proteins.

The growth in the mRNA platform market is driven by several factors, including the increasing incidence of infectious diseases, advancements in mRNA technology, and significant investments in biotechnology research. The ongoing threat of pandemics and the need for swift and effective responses have highlighted the importance of mRNA vaccines, spurring demand and investment in this technology. Technological advancements, such as improved delivery systems and more efficient manufacturing processes, have enhanced the scalability and efficacy of mRNA-based products. Furthermore, substantial investments from both public and private sectors are accelerating research and development activities, leading to new therapeutic applications and expanding the market potential. Regulatory support and expedited approval processes for mRNA vaccines and therapies have also contributed to the rapid growth of this market. These factors collectively underscore the transformative impact of the mRNA platform in modern medicine and its potential to address a wide range of health challenges.

Select Competitors (Total 96 Featured) -

• AstraZeneca PLC
• Asuragen, Inc.
• Catalent Pharma Solutions
• Altogen Labs
• Arcturus Therapeutics, Inc.
• BioNTech AG
• CRISPR Therapeutics
• Aldevron
• AKESOgen, Inc.
• baseclick GmbH
• chimeron bio
• Acuitas Therapeutics
• Accent Therapeutics
• Accanis Biotech F&E GmbH & Co KG
• Avectas

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.